Health

Results: 1-12 of 9475

Business Wire logo

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Leqembi Iqlik® for initiation treatment launched in the US

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Amaris Mint BioBoost nutrition range

CLINICIAN-FOUNDED AMARIS MINT(R) CONFIRMS UK AVAILABILITY OF SWEDISH-MADE BIOBOOST NUTRITION RANGE

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

Business Wire logo

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

Business Wire logo

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

PR Newswire associated0

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Takeshi Mori, Novotech Country Head, Japan

Novotech Strengthens Presence in Japan with Opening of Tokyo Office

PR Newswire associated0

LumenStim Prepares to Launch Next-Generation Teeth Whitening System on Kickstarter

Keymed Biosciences Announces 2026 H1 Results and Business Updates